Vertex Pharma's Hepatitis C Drug Gets Priority Review
January 24, 2011
Cambridge, Mass.-based Vertex Pharmaceuticals Inc. reports its experimental hepatitis C drug telaprevir has been granted priority review status from regulators in both the United States and Canada. Vertex, which in November asked the US Food and Drug Administration for a priority review of data on telaprevir, said FDA has set May 23 as the action date to decide whether to approve the drug. Priority review status cuts four months off the time FDA needs to approve a drug, Vertex said. Health Canada's move to allow priority review will shorten the review period there from 18 or more months down to six to nine months.
This article was provided by U.S. Centers for Disease Control and Prevention. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update. Visit the CDC's website to find out more about their activities, publications and services.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)